| Resum: | Patients with coronavirus disease 2019 (COVID-19) infection can suffer from a variety of neurological disorders; therefore, there is a demand to investigate specific treatments. As a part of this endeavor, academic databases related to clinical, neuropathological, and immunological biomarkers were examined for searching promising drugs to treat neurological disorders in the COVID-19 group. Also, the neuroprotective potential of herbs for patients with post-COVID-19 has been evaluated using PubMed, MEDLINE, Scopus, EMBASE, Google Scholar, EBSCO, Web of Science, Cochrane Library, WHO database, and ClinicalTrials.gov. The terms used for the Boolean search were Indian herbs and neuroprotective potential, post-COVID-19 symptoms, and so on. Based on our knowledge, nervous system immunity is an inherent characteristic of the nervous system because it is highly immunologically active. It was found that patients infected with COVID-19 often experience neurological symptoms such as muscle pain, headaches, confusion, dizziness, and loss of smell and taste. The most commonly used herbs for neurological disorders are Bacopa monnieri, Mucuna pruriens, Withania somnifera, Acorus calamus, Phyllanthus emblica, Blumea balsamifera, Asparagus racemosus, Cannabis sativa, Convolvulus prostratus, Swertia chirata, Vitex negundo, Nyctanthes arbor-tristis Linn, Centella asiatica, Curcuma longa, Ocimum tenuiflorum. It is widely recognized that herbal drugs have the potential for treating neurological diseases such as Parkinson’s, Alzheimer’s, and cerebrovascular diseases in COVID-19 patients. However, clinical trials are still limited. The suitability of drugs depends on the investigation of biomarkers and pathobiological mechanisms. Thus, it is necessary to use modern scientific approaches and technologies to conduct comprehensive mechanistic studies to understand the therapeutic potential of herbs for neurological disorders associated with the SARS-CoV-2 infection.
|
